Triple-Drug cocktail shows promise against tough blood cancer
NCT ID NCT04855695
First seen Jan 24, 2026 · Last updated May 20, 2026 · Updated 15 times
Summary
This study is testing a combination of three drugs (acalabrutinib, venetoclax, and obinutuzumab) for people with mantle cell lymphoma, a type of blood cancer. It includes both patients whose cancer has come back or not responded to prior treatment, as well as those who have not yet been treated. The goal is to see if this drug combo can make the cancer disappear completely and keep it away for as long as possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beth Israel Deaconess Medical Center
RECRUITINGBoston, Massachusetts, 02215, United States
Contact Phone: •••-•••-••••
-
Dana-Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
Contact Phone: •••-•••-••••
Contact
-
University of Chicago Medical Center
RECRUITINGChicago, Illinois, 60637, United States
Contact
Conditions
Explore the condition pages connected to this study.